Charles A.  Reinhart, III net worth and biography

Charles Reinhart, III Biography and Net Worth

In 2016, Charles A. Reinhart III joined Pacira as Chief Financial Officer, responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis, and investor relations.

Prior to joining Pacira, Mr. Reinhart served as Chief Financial Officer of Covis Pharmaceuticals, Inc. From September 2011 to August 2014, he served as Executive Vice President and Chief Financial Officer of Archimedes Pharma Ltd. Mr. Reinhart also served as Senior Vice President and Chief Financial Officer of PharmAthene, Inc., a biodefense company engaged in the development of next generation medical countermeasures against biological and chemical threats, from 2009 to 2011. He has also held senior financial roles at Millennium Pharmaceuticals, Inc., Cephalon, Inc. and several early-stage life sciences companies. He also served as a director of Osiris Therapeutics, Inc. (Nasdaq: OSIR) from September 2018 until it was acquired in April 2019. Mr. Reinhart has successfully built and managed finance organizations within rapidly growing companies, responsible for accounting and financial reporting, financial planning and analysis, tax, treasury, risk management and procurement. He has worked closely with commercial teams to evaluate sales operations, monitor product pricing and implement contracting strategies. In addition, he has significant experience in investor relations, corporate development and capital raising. He has been integrally involved in equity and debt financing transactions, as well as the evaluation, acquisition and integration of multiple products and companies.

Mr. Reinhart earned his Bachelor of Science degree from Lehigh University and his MBA from the Wharton School of the University of Pennsylvania. He is also a CPA.

What is Charles A. Reinhart, III's net worth?

The estimated net worth of Charles A. Reinhart, III is at least $918,321.28 as of June 6th, 2023. Mr. Reinhart, III owns 34,997 shares of Pacira BioSciences stock worth more than $918,321 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Reinhart, III may own. Learn More about Charles A. Reinhart, III's net worth.

How do I contact Charles A. Reinhart, III?

The corporate mailing address for Mr. Reinhart, III and other Pacira BioSciences executives is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. Pacira BioSciences can also be reached via phone at (813) 553-6680 and via email at [email protected]. Learn More on Charles A. Reinhart, III's contact information.

Has Charles A. Reinhart, III been buying or selling shares of Pacira BioSciences?

Charles A. Reinhart, III has not been actively trading shares of Pacira BioSciences within the last three months. Most recently, Charles A. Reinhart III sold 1,236 shares of the business's stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $38.99, for a transaction totalling $48,191.64. Following the completion of the sale, the chief financial officer now directly owns 34,997 shares of the company's stock, valued at $1,364,533.03. Learn More on Charles A. Reinhart, III's trading history.

Who are Pacira BioSciences' active insiders?

Pacira BioSciences' insider roster includes Donald Manning (Insider), Max Reinhardt (Insider), Charles Reinhart, III (CFO), Lauren Riker (VP), David Stack (CEO), Andreas Wicki (Director), Kristen Williams (Insider), and Roy Winston (Insider). Learn More on Pacira BioSciences' active insiders.

Are insiders buying or selling shares of Pacira BioSciences?

In the last twelve months, insiders at the sold shares 16 times. They sold a total of 138,857 shares worth more than $4,613,719.15. The most recent insider tranaction occured on March, 8th when Director Gary W Pace sold 90,000 shares worth more than $2,754,000.00. Insiders at Pacira BioSciences own 6.6% of the company. Learn More about insider trades at Pacira BioSciences.

Information on this page was last updated on 3/8/2024.

Charles A. Reinhart, III Insider Trading History at Pacira BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/6/2023Sell1,236$38.99$48,191.6434,997View SEC Filing Icon  
6/6/2022Sell2,516$61.37$154,406.9228,283View SEC Filing Icon  
6/4/2021Sell2,648$61.04$161,633.9224,799View SEC Filing Icon  
6/4/2020Sell1,489$46.33$68,985.3714,847View SEC Filing Icon  
6/4/2019Sell1,106$42.91$47,458.4611,936View SEC Filing Icon  
6/4/2018Sell708$33.02$23,378.168,042View SEC Filing Icon  
See Full Table

Charles A. Reinhart, III Buying and Selling Activity at Pacira BioSciences

This chart shows Charles A Reinhart III's buying and selling at Pacira BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pacira BioSciences Company Overview

Pacira BioSciences logo
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Read More

Today's Range

Now: $26.33
Low: $25.33
High: $26.37

50 Day Range

MA: $28.71
Low: $25.50
High: $31.41

2 Week Range

Now: $26.33
Low: $25.33
High: $48.60

Volume

304,606 shs

Average Volume

489,735 shs

Market Capitalization

$1.22 billion

P/E Ratio

32.51

Dividend Yield

N/A

Beta

0.76